Dec 26, 2017 11:41 am EST UPDATE - Rezolute, Inc. Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital Fund, LLC
Dec 7, 2017 8:30 am EST AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc.
Oct 17, 2017 8:00 am EDT AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates for the Treatment of Diabetic Retinopathy, Diabetic Macular Edema and Hereditary Angioedema
Aug 7, 2017 8:00 am EDT AntriaBio and ActiveSite Pharmaceuticals Announce License and Development Agreement for Plasma Kallikrein Inhibitors
Jul 17, 2017 8:00 am EDT AntriaBio Announces $13 Million Close of Private Placement Transaction and Plan to Dose First Patient with AB101 This Month
Jun 5, 2017 8:00 am EDT AntriaBio Files Investigational New Drug Application for Once-Weekly Basal Insulin AB101
May 1, 2017 8:00 am EDT AntriaBio Formally Engages CRO for the Conduct of its Phase I First-in-Human Clinical Trial of AB101
